DNAprint Genomics (DNAG)

[dr frudaky]

wrl

I cannot share your enthusiasm for that increase in revenues. The amount, placed in perspective, is miniscule and does not even begin to offset the humongous losses continually being sustained in operational cash burn. The company can continue its forensics/ancestry initiatives and contract research/analytical services with modest increases in revenues, but that will not do anything for the overall picture or shareholder value.

The drug pipeline and personalized medicine initiatives are too nascent to even suggest commercial revenue streams from those products for several more years down the road...if ever.

The company will have a very difficult time if some reasonable financing is not secured by the end of this year, at which point it will have no other choice but to go back to the toxic financiers with hat in hand and hope the second r/s will not completely decimate the holdings of the current shareholders.

I would like to see some tangible optimistic scenario out of this financial plight, but there does not appear to be anything visible on the horizon.

JMHO for your kind consideration.

dr f